References
- Alam, N., Koul, M., Mintoo, M. J., Khare, V., Gupta, R., Rawat, N., Sharma, P. R., Singh, S. K., Mondhe, D. M., & Gupta, P. N. (2017). Development and characterization of hyaluronic acid modified PLGA based nanoparticles for improved efficacy of cisplatin in solid tumor. Biomedicine & Pharmacotherapy, 95, 856–864. https://doi.org/https://doi.org/10.1016/j.biopha.2017.08.108
- Amjadi, I., Rabiee, M., & Hosseini, M.-S. (2013). Anticancer activity of nanoparticles based on PLGA and its co-polymer: In-vitro evaluation. Iranian Journal of Pharmaceutical Research: IJPR, 12(4), 623–634.
- Åqvist, J., Luzhkov, V. B., & Brandsdal, B. O. (2002). Ligand binding affinities from MD simulations. Accounts of Chemical Research, 35(6), 358–365. https://doi.org/https://doi.org/10.1021/ar010014p
- Bai, L., Smith, D. C., & Wang, S. (2014). Small-molecule SMAC mimetics as new cancer therapeutics. Pharmacology & Therapeutics, 144(1), 82–95. https://doi.org/https://doi.org/10.1016/j.pharmthera.2014.05.007
- Baiti, R. N., Ardhyananta, H., & El Kirat, K. (2015). Effect of acidic and basic environment to the degradation behavior of PLGA nanocapsules for biomedical application. Advanced Materials Research, https://doi.org/https://doi.org/10.4028/www.scientific.net/AMR.1123.213
- Brunckhorst, M. K., Lerner, D., Wang, S., & Yu, Q. (2012). AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer. Cancer Biology & Therapy, 13(9), 804–811. https://doi.org/https://doi.org/10.4161/cbt.20563
- Chang, D., Li, H., Qian, C., & Wang, Y. (2019). DiOHF protects against doxorubicin-induced cardiotoxicity through ERK1 signaling pathway. Frontiers in Pharmacology, 10, 1081. https://doi.org/https://doi.org/10.3389/fphar.2019.01081
- Chereddy, K. K., Her, C.-H., Comune, M., Moia, C., Lopes, A., Porporato, P. E., Vanacker, J., Lam, M. C., Steinstraesser, L., Sonveaux, P., Zhu, H., Ferreira, L. S., Vandermeulen, G., & Préat, V. (2014). PLGA nanoparticles loaded with host defense peptide LL37 promote wound healing. Journal of Controlled Release: Official Journal of the Controlled Release Society, 194, 138–147. https://doi.org/https://doi.org/10.1016/j.jconrel.2014.08.016
- Childs, A. C., Phaneuf, S. L., Dirks, A. J., Phillips, T., & Leeuwenburgh, C. (2002). Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2: Bax ratio. Cancer Research, 62(16), 4592–4598.
- Du, C., Fang, M., Li, Y., Li, L., & Wang, X. (2000). Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell, 102(1), 33–42. https://doi.org/https://doi.org/10.1016/s0092-8674(00)00008-8
- Finlay, D., Teriete, P., Vamos, M., Cosford, N. D., & Vuori, K. (2017). Inducing death in tumor cells: Roles of the inhibitor of apoptosis proteins. F1000Research, 6, 587. https://doi.org/https://doi.org/10.12688/f1000research.10625.1
- Fulda, S. (2017). Smac mimetics to therapeutically target IAP proteins in cancer. International Review of Cell and Molecular Biology, 330, 157–169.
- Gidwani, B., & Vyas, A. (2017). Pharmacokinetic study of solid-lipid-nanoparticles of altretamine complexed epichlorohydrin-β-cyclodextrin for enhanced solubility and oral bioavailability. International Journal of Biological Macromolecules, 101, 24–31. https://doi.org/https://doi.org/10.1016/j.ijbiomac.2017.03.047
- Iqbal, M., Zafar, N., Fessi, H., & Elaissari, A. (2015). Double emulsion-solvent evaporation techniques used for drug encapsulation. International Journal of Pharmaceutics, 496(2), 173–190. https://doi.org/https://doi.org/10.1016/j.ijpharm.2015.10.057
- Kaiser, E., Colescott, R., Bossinger, C., & Cook, P. (1970). Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Analytical Biochemistry, 34(2), 595–598. https://doi.org/https://doi.org/10.1016/0003-2697(70)90146-6
- Kulathila, R., Vash, B., Sage, D., Cornell-Kennon, S., Wright, K., Koehn, J., Stams, T., Clark, K., & Price, A. (2009). The structure of the BIR3 domain of cIAP1 in complex with the N-terminal peptides of SMAC and caspase-9. Acta Crystallographica. Section D, Biological Crystallography, 65(Pt 1), 58–66. https://doi.org/https://doi.org/10.1107/S0907444908039243
- Kumari, A., Singla, R., Guliani, A., & Yadav, S. K. (2014). Nano-encapsulation for drug delivery. EXCLI Journal, 13, 265–286.
- Lungu, I. I., Grumezescu, A. M., Volceanov, A., & Andronescu, E. (2019). Nanobiomaterials used in cancer therapy: An up-to-date overview. Molecules, 24(19), 3547. https://doi.org/https://doi.org/10.3390/molecules24193547
- Makadia, H. K., & Siegel, S. J. (2011). Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers, 3(3), 1377–1397. https://doi.org/https://doi.org/10.3390/polym3031377
- Mohammadi-Samani, S., & Taghipour, B. (2015). PLGA micro and nanoparticles in delivery of peptides and proteins; problems and approaches. Pharmaceutical Development and Technology, 20(4), 385–393. https://doi.org/https://doi.org/10.3109/10837450.2014.882940
- Nejabat, M., Eisvand, F., Soltani, F., Alibolandi, M., Mohammad Taghdisi, S., Abnous, K., Hadizadeh, F., & Ramezani, M. (2020). Combination therapy using smac peptide and doxorubicin-encapsulated MUC 1-targeted polymeric nanoparticles to sensitize cancer cells to chemotherapy: An in vitro and in vivo study. International Journal of Pharmaceutics, 587, 119650. https://doi.org/https://doi.org/10.1016/j.ijpharm.2020.119650
- Rathore, R., McCallum, J. E., Varghese, E., Florea, A.-M., & Büsselberg, D. (2017). Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs). Apoptosis : An International Journal on Programmed Cell Death, 22(7), 898–919. https://doi.org/https://doi.org/10.1007/s10495-017-1375-1
- Rizvi, S. A., & Saleh, A. M. (2018). Applications of nanoparticle systems in drug delivery technology. Saudi Pharmaceutical Journal: SPJ: The Official Publication of the Saudi Pharmaceutical Society, 26(1), 64–70. https://doi.org/https://doi.org/10.1016/j.jsps.2017.10.012
- Rosyada, A., Sunarharum, W., & Waziiroh, E. (Eds.). (2019). Characterization of chitosan nanoparticles as an edible coating material. In IOP Conference Series: Earth and Environmental Science. IOP Publishing.
- Servida, F., Lecis, D., Scavullo, C., Drago, C., Seneci, P., Carlo-Stella, C., Manzoni, L., Polli, E., Lambertenghi Deliliers, G., Delia, D., & Onida, F. (2011). Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis. Investigational New Drugs, 29(6), 1264–1275. https://doi.org/https://doi.org/10.1007/s10637-010-9475-6
- Sharma, S. K., Straub, C., & Zawel, L. (2006). Development of peptidomimetics targeting IAPs. International Journal of Peptide Research and Therapeutics, 12(1), 21–32. https://doi.org/https://doi.org/10.1007/s10989-005-9003-2
- Sun, H., Nikolovska-Coleska, Z., Yang, C.-Y., Qian, D., Lu, J., Qiu, S., Bai, L., Peng, Y., Cai, Q., & Wang, S. (2008). Design of small-molecule peptidic and nonpeptidic Smac mimetics. Accounts of Chemical Research, 41(10), 1264–1277. https://doi.org/https://doi.org/10.1021/ar8000553
- Tacar, O., Sriamornsak, P., & Dass, C. R. (2013). Doxorubicin: An update on anticancer molecular action, toxicity and novel drug delivery systems. Journal of Pharmacy and Pharmacology, 65(2), 157–170. https://doi.org/https://doi.org/10.1111/j.2042-7158.2012.01567.x
- Uciechowska, U., Schemies, J., Scharfe, M., Lawson, M., Wichapong, K., Jung, M., & Sippl, W. (2012). Binding free energy calculations and biological testing of novel thiobarbiturates as inhibitors of the human NAD + dependent histone deacetylase Sirt2. MedChemComm, 3(2), 167–173. https://doi.org/https://doi.org/10.1039/C1MD00214G